Melissa Bamberg, NodPod Founder, Giving 25% Off NodPod Orders To Help People Sleep During Stressful Coronavirs Pandemic

nodpod

“At nodpod, good sleep is the center of everything we stand for and it's everything we believe in. If you sleep better, you live better.”

LOS ANGELES, CA, UNITED STATES, March 31, 2020 /EINPresswire.com/ — The outbreak of coronavirus disease 2019 (COVID-19) may be stressful for everyone. Fear and anxiety about a disease can be overwhelming and cause strong emotions in people of all ages. Taking care of yourself is the most important thing we can do right now. One of the leading practices that can help decrease stress, according to the CDC, is to get plenty of sleep. Stress and sleep are closely linked. Stress can adversely affect sleep quality and duration, while insufficient sleep can increase stress levels. Both stress and a lack of sleep can lead to lasting physical and mental health problems.

Melissa Bamberg, nodpod Founder, has much to say on the crucial need of sleep during these difficult times. “At nodpod, good sleep is the center of everything we stand for and it's everything we believe in. If you sleep better, you live better. We are extremely passionate about the benefits of ‘deep touch pressure’ which is the way in which our body responds to gentle, constant pressure. As opposed to a tickle on your neck which alerts your central nervous system, gentle pressure has the opposite effect. It is very calming and soothing; it works almost immediately naturally releasing serotonin and melatonin- both important chemicals in helping you to feel relaxed and get your best sleep."

For those who are in need of a good night sleep during these crazy and stressful times, nodpod is here to help. nodpod, “The Weighted Blanket for Your Eyes”, is a patented weighted sleep mask that is like a hug for your head. This weighted eye mask features four microbead-filled pods that not only block out the light, but also apply gentle pressure on your eyes to help you fall asleep faster and better. Featuring a cool jersey cotton surface with a warm microfleece reverse, this sleep therapy mask can be used to keep you comfy in all seasons, while the open-ended design ensures that you'll stay comfortable in different sleeping positions.

With nodpod, you can sleep in any position. Just lay it over your eyes, and sink into your best night’s sleep. There’s no uncomfortable strap or velcro. The scent-free microbeads create a custom fit that perfectly blocks light while the gentle weight naturally reduces stress and anxiety. nodpod thinks about the bigger picture and their product isn’t just about blocking light, it’s about helping your body naturally relax and get the deep, restorative sleep that it needs. Reducing negative energies in our body is of utmost importance in this pandemic so that we can remain physically and mentally healthy. That’s why great sleep matters. When we get good sleep, we are able to handle stressful situations better, like the one we are in now.

This is why nodpod is offering 25% off your entire order during this time with the sleep code: SLEEPMATTERS. To ensure customers of the best health practices, nodpod has their inventory stored in their own warehouse. Therefore, they have complete control over how they are handling the COVID situation. “We are all working from home, but we have one dedicated staff member that fills daily orders from our warehouse,” states nodpod. You do not have to worry about nodpod’s products being exposed.

nodpod is a great sleep product and has been recognized by health industry professionals. Dr. McKinney, a California Emergency Room Doctor states, “Tension and anxiety are a part of people's lives in more ways than we’ve ever seen before. Stress and anxiety have real physical manifestations, most importantly sleeplessness. I recommend nodpod for its ability to ease tension and bring about relaxation to help the body sleep naturally." nodpod is the real deal and if you want the best sleep during these stressful times, nodpod has what you are looking for.

nodpod Contact Here:

hello@nodpod.com

1-888-486-4224

https://nodpod.com/

Aurora DeRose
Michael Levine Media
+1 310-396-6090
email us here


Source: EIN Presswire

Only Wide-Scale Use of a Fully At-Home Test Will Make a Dent in COVID-19

An at-home blood test that uses a finger prick to sample blood.

We already have a great prototype for an at-home blood test, and millions of Americans already use it every day.

To win this war and save American lives, we need an at-home sampling and processing blood test, and we need it soon.

BOSTON, MASSACHUSETTS, UNITED STATES, March 31, 2020 /EINPresswire.com/ — There was justifiable excitement when Abbott announced a new 5-minute test for COVID-19, the disease caused by the novel coronavirus. More rapid and widespread testing at point-of-care will do much to help us win this war.

Ultimately, though, hospital-based or office-based testing devices, like Abbotts, aren’t going to make a big-enough dent in this battle. Only at-home sample collecting and processing will truly help us get our arms around this enormously difficult to defeat new enemy and defeat it.

In my earlier article, I outlined a 3-step plan to save lives. The third, and arguably most important, step of that plan is the rapid wide-scale deployment of a fully at-home blood test for COVID-19. In this article, I will more fully explain why this is so critical, and so doable, financially, technologically and psychologically.

WE ALREADY HAVE A PROTOTYPE UNDER WIDESPREAD USE

Can you imagine a diabetic going to the hospital four times a day, 365 days a year, to get his or her blood-sugar level tested? Because diabetics need frequent, easy-to-use blood tests, the market responded with an at-home sampling AND processing kit that helps millions of American diabetics manage their condition fully at-home.

Without this tool, it is safe to assume that many diabetics would be flying blind, living their lives at the whims of an invisible killer – much as we are today with the coronavirus.

The 5-minute Abbott test is a game-changer, to be sure. The President, the FDA, and private business should be applauded for expediting its development and approval.

But touting it as a patient/consumer-centered test is misleading. It’s only a “5-minute test” if you live at a hospital or doctor’s office. For many Americans, particularly those who rely on public transportation, the start-to-finish testing process could actually consume at least four-and-a-half hours.

This, obviously, is an impractical and psychologically intolerable amount of time for most Americans, if you want them to test themselves (and others) every time they seek entry back into their “virus-free” homes. Yet, this would be the price they would have to pay, daily, if they went back to work at their plant or office.

If you were a soldier in a foxhole, would it be reasonable to expect you to spend four hours every time you need to get a bullet to fire your next round?

HERE'S EXACTLY WHAT WE NEED

What we need to win the war as soon as possible is a test kit having ALL of the following features:

1. Very fast results: If we plan to keep our homes a virus-free safe haven, we need to be able to quickly test anyone who seeks entry into it. This means we need super-fast (no longer than 15-minutes, and preferably 5-minutes) sampling and processing, combined, i.e. as fast as the current finger-prick blood sugar testing.
2. Mobile: So we can use it at home or on the road.
3. Convenient: Easy-to-carry and low-profile, so that it can be kept in the average entry way.
4. Ease-of-use: A simple finger prick should do it. The current nasal- and throat-swabs are difficult to do correctly (meaning a high, very dangerous, false-negative rate) and painful for the patient.
5. No time, energy, or transportation costs: Quick, easy, and at-home.
6. Low-aggregate costs: No personnel or labs needed to sample or interpret results.
7. No prior-authorization needed: Nobody should need an order from their doctor to quickly learn if they have COVID-19. Test can be done any time, day or night.
8. High-quality and “idiot-proof”: No medical – or even high school – degree needed.
9. Safe and effective: Proven repeatedly over many years of use.
10. Highly accurate: Very low error rate, especially dangerous false-negative rate

THREE COMPANIES READY TO ROLL

I personally know of three companies that, if soon they receive adequate funding for further development, manufacturing, and distribution, and robust regulatory support, can very quickly help us accomplish the goal of having a large-scale at-home-test program that could meet these requirements, nationwide.

Why are all of those features of great importance? Because, if the tests aren’t widely and aggressively used, we won’t come close to being able to save, by my count, 50,000 American lives. It would be like performing D-Day with only 1,000 soldiers, instead of 156,000.

Gen. Eisenhower didn’t do it, and I don’t believe President Trump will either. He is looking for “The One Big Thing,” a knock-out punch.

Based on my decades of experience in the health sciences, including previously serving as the Principal Deputy Commissioner of the U.S. Food and Drug Administration, I know that at-home-sample-collection and processing, which will help us accomplish aggressive testing in enormous numbers, is the only way we are going to win this war.

This is doable. We just need our leaders to make this Phase I of my plan happen, very, very soon.

The Hon. John Norris is an FDA Former Principal Deputy Commissioner, a Harvard Former Health Policy and Management Faculty Member, a Massachusetts Former Chairman of the Clinical Laboratory Regulation Reform Commission, and Chairman of FDTH Regulatory Affairs Strategies, as well as an inventor-entrepreneur and frequent drug, device, Healthcare-IT, clinical lab, and hospital-system visionary, innovator, advisor, and board member. He can be reached at john.norris.jd.mba@fdthregulatoryaffairsstrategies.com.

John Norris
FDTH Regulatory Affairs Strategies
+1 617-680-3127
email us here


Source: EIN Presswire

Company That just Released World’s First Saliva Test for Autism Opens Up Investment Opportunity to the Public

Quadrant Biosciences logo, invest, epigenetics, autism

Quadrant Biosciences

Quadrant Biosciences offers common shares through equity crowdfunding platform

SYRACUSE, NEW YORK, UNITED STATES, March 31, 2020 /EINPresswire.com/ — Company That just Released World’s First Saliva Test for Autism Opens Up Investment Opportunity to the Public

Quadrant Biosciences offers common shares through equity crowdfunding platform

Quadrant Biosciences Inc (“Quadrant Biosciences”), a leading developer of epigenetic diagnostic solutions, including the world's first saliva test for autism, announced that it is now offering common shares of the company (at a price of $3/share, with a minimum investment of $300) through equity crowdfunding platform Wefunder. The Reg A plus campaign is Quadrant’s first offering of common shares to the public — the company has previously raised over $32 million through private sales of its common shares to accredited investors only.

Quadrant Biosciences is a life science company that leverages new discoveries in the field of epigenetics and microbiome research to develop novel diagnostic solutions to many of today's critical health care challenges. In December, the company commercially released Clarifi ASD™, the first of its kind epigenetic saliva test to aid the diagnosis of autism in children 18 months through six years of age. Quadrant Biosciences collaborated with researchers from SUNY Upstate Medical University and Penn State College of Medicine to create this novel biological test that is based on the genetic sequencing and molecular analysis of regulatory RNAs and microbes in the saliva.

Clarifi ASD™is the first product to be launched from the company's Clarifi™ Epigenetic Diagnostic Platform. According to Quadrant CEO and Founder Richard Uhlig, several other tests using the same epigenetic research and next-generation sequencing technology are currently under research and development. “Our collaborative research with SUNY Upstate Medical and Penn State College of Medicine has shown that the same approach we used for developing the Clarifi autism saliva test – evaluating epigenetic molecules found in the saliva – is demonstrating similar diagnostic utility for other neurological diseases such as Parkinson's Disease and Concussion Injuries. It is exciting and extremely gratifying to be on the forefront of these life-changing discoveries.”

Prospective investors interested in learning more about Quadrant Biosciences and the investment opportunity can review offering documents and other information about the company at https://www.quadrantbiosciences.com/investor-relations/

AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM HERE. YOU SHOULD READ THE OFFERING CIRCULAR BEFORE MAKING ANY INVESTMENT.
See the NCPS Offerings Disclosure here.
Securities offered through North Capital Private Securities, member FINRA/SIPC.

Investment risk – liquidity, risk of loss; Not tax, investment, accounting advice; past performance not indicative of future results; consult with a professional (attorney, advisor, accountant); conduct your own research and due diligence; forward looking statements; information believed to be correct but don't rely upon it / no warranty; not an offer to sell securities; information may not be complete; investments not suitable for all investors; not a recommendation; platforms are not brokers; member FINRA and SIPC

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
.
About Quadrant Biosciences
Quadrant Biosciences is a life science company involved in the development of functional assessments and epigenetic diagnostic solutions for large-scale health issues. The company has entered into collaborative research relationships with a number of institutions including SUNY Upstate Medical University and Penn State University to explore and develop novel biomarker technologies with a focus on Autism Spectrum Disorder, concussion, and Parkinson's Disease. Quadrant Biosciences also participates in the Start-up NY program, a New York State economic development program. For more information, please visit www.quadrantbiosciences.com.

David MacLean
Quadrant Biosciences
+1 315-614-2325
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Singapore Pharmaceutical Market Outlook 2017-2030 – by Goldstein Market Intelligence

, In 2016, Singapore government invested around USD 13 billion in the development of healthcare facilities in the region.

NEW YORK, NY, UNITED STATES OF AMERICA, March 31, 2020 /EINPresswire.com/ — Singapore Pharmaceutical Market Outlook 2017-2030 – by Goldstein Market Intelligence

According to the Goldstein Market Intelligence forecast, In 2016, Singapore government invested around USD 13 billion in the development of healthcare facilities in the region. As per Ministry of Singapore Health, there were 12,000 hospital beds in 25 hospitals and specialty centers in Singapore.
A more recent investment of $1 billion to develop several research institutes and the Biopolis R&D complex. Together, the investments have attracted more than 30 major global life-sciences companies and created an effective ecosystem that harnesses the benefits of economies of scale and knowledge transfer. The first tier of protection comprises government subsidies of up to 80 percent of the total cost of care provided in public hospitals and primary care polyclinics. This is supported by a group of savings and insurance programs known as the “3Ms” system—for Medisave, MediShield, and Medifund—which plays a critical role in maintaining the public’s health and welfare.

Report is available at :- https://bit.ly/2Uv4YIp
Market dynamic / Drivers & Restraints to Market Growth
Increase in aging population and focusing on fitness & healthy lifestyle is predicted to rise the Singapore pharmaceuticals market. Rise in aging population in many nations across the globe is a major a growth driver for the pharmaceutical industry. Occupational stress across diverse work settings including job insecurity, work hours, job quality (job strain, job control) and wages.
Meanwhile, the innovative pharmaceutical industry is currently facing unprecedented challenges caused by slower sales growth, expiring patents, increasing competition from generics, shorter product life cycles, tighter regulations, adverse media coverage and reputational damage, and a decline in the number of new innovative drugs under development.

Request for Sample Report at :- https://bit.ly/2WSoHDI

Covered in this Singapore Pharmaceutical Market Outlook 2030 Report are
“Singapore Pharmaceutical Market Outlook 2030” by Goldstein Research contains detailed overview of Singapore Pharmaceutical Market in terms of market segmentation by analysis basis, therapy type and geography. The Report highlights the competitive outlook of major global players that includes the business strategies, product portfolio, revenue distribution, financial analysis, R&D activities, and investments. The in-depth analysis of POS Terminal Market report will help the clients to assess their business strategies as per the competitive environment in the market space.

Major players covered in this POS Terminal Market report are:
• GlaxoSmithKline (GSK)
• Abbot Laboratories
• Lonza
• Merck Sharp & Dohme
• Takeda
• Roche Holding AG
• Pfizer Inc.
• Raffles Medical Group Ltd.
• Wave Life Sciences
• Sphaera Pharma
• Special Access Pharma
• Pharmaskin
• NCI Health
• Melbourne Drugs

Further, Singapore Pharmaceutical Market Report encompasses the major trends & opportunities, market dynamics and other growth factors of the market Singapore Pharmaceutical Market outlook also comprises of key challenges, risk analysis, BPS analysis, SWOT Analysis and Market Attractiveness. The report also highlights the expert analysis to provide a complete overview of the market including the PESTLE analysis of each region and country.
About Goldstein Research
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear-cut forecasts. Our market research reports provide in-depth analysis of global and regional variations along with competitors’ overview.
Our analysts working on chemicals construction to help various tech-giants, tech start-ups and entry players to assess the current and upcoming business scenario. We believe in the vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.

Contact for more Info:

Dennis Abraham
(Global Sales Head)

UK:
+44 7520 644482
dennis.abraham@goldsteinresearch.com
www.goldsteinresearch.com

Steve Blades
Goldstein Research
+1 646-568-7747
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Silica Aerogel Exports From China 2017-2030 Outlook – By Goldstein Market Intelligence

Changzhou National Hi-Tech District consented to an arrangement,underneath which China greatest aerogel materials fabricating base will be built up in locale.

NEW YORK, NY, UNITED STATES OF AMERICA, March 31, 2020 /EINPresswire.com/ — Silica Aerogel Exports From China 2017-2030 Outlook – By Goldstein Market Intelligence
According to the Goldstein Market Intelligence report , Changzhou National Hi-Tech District consented to an arrangement, underneath which China's greatest aerogel materials fabricating base will be built up in the locale. Changzhou National Hi-Tech District intends to place in an excited assurance to acquire more than 10 aerogel creation offices inside five years, with the conviction of delivering a yield esteem anticipated at 10 billion yuan (approx. USD 1.5 billion).
Silica aerogel warm protection in current structures has become a basic method to meet the troubles of upgraded vitality productivity, by which the conduction of warmth through dividers, roofs, windows rooftops and floors can be impeded effectively. In addition, rising interest from North America and European markets will give the significant lift to the Chinese aerogels fabricating industry.

Report is available at:- https://bit.ly/2UOiOEN
Covered in this China Silica Aerogel Exports Market Report are
“China Silica Aerogel Exports Market Outlook 2030” by Goldstein Research contains detailed overview of China Silica Aerogel Exports Market in terms of market segmentation by analysis basis, therapy type and geography. The Report highlights the competitive outlook of major global players that includes the business strategies, product portfolio, revenue distribution, financial analysis, R&D activities, and investments. The in-depth analysis of China Silica Aerogel Exports Market report will help the clients to assess their business strategies as per the competitive environment in the market space.
Major players covered in this China Silica Aerogel Exports Market report are:
Aspen Aerogels
Cabot Corporation
Aerogel Technologies
Nano High-Tech
Guangdong Alison Hi-Tech
Active Aerogels
Enersens
Jios Aerogel Corporation
Insulgel High-Tech
Protective Polymers
BASF
Guizhou Aerospace
Green Earth
Aerogel Technologies (GEAT).

Request for Sample Report at:- https://bit.ly/3bGfouQ
Further, China Silica Aerogel Exports Market Report encompasses the major trends & opportunities, market dynamics and other growth factors of the market. China Silica Aerogel Exports Market outlook also comprises of key challenges, risk analysis, BPS analysis, SWOT Analysis and Market Attractiveness. The report also highlights the expert analysis to provide a complete overview of the market including the PESTLE analysis of each region and country.
About Goldstein Research
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear-cut forecasts. Our market research reports provide in-depth analysis of global and regional variations along with competitors’ overview.
Our analysts working on chemicals construction to help various tech-giants, tech start-ups and entry players to assess the current and upcoming business scenario. We believe in the vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.

Contact for more Info:

Dennis Abraham
(Global Sales Head)

UK:
+44 7520 644482
dennis.abraham@goldsteinresearch.com
www.goldsteinresearch.com

Steve Blades
Goldstein Research
+1 646-568-7747
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

ExAM4Inspections providing standardized Infectious Disease Control software to hospitals

ExAM4Inspections.com Logo

ExAM4Inspections.com

MBA Logo

MBA Logo

MB&A providing its ExAM4Inspections.com solution supporting infectious disease control and healthcare associated infection solutions to the healthcare market.

Our IDC and HAI accelerators will enable our customers to get programs started faster than ever before which is especially important right now as we work to stop the spread of COVID-19.”

— Bradley Hilker, Strategic Account Executive

ARLINGTON, VIRGINIA, UNITED STATES, March 31, 2020 /EINPresswire.com/ — Millsapps, Ballinger & Associates, LLC (MB&A) announced that they are delivering standardized rollout and delivery of the companies ExAM4Inspections.com Salesforce AppExchange product (ExAM) in support of Infectious Disease Control (IDC) and Healthcare Associated Infections (HAI). The approach has been used at more than a dozen hospitals to date and promises a standardized and rapid on boarding that helps hospitals respond to the need to control infectious diseases.

The standardization of key programs ExAM supports such as Hand Hygiene (HH), Sterile Processing, Operating Room Inspections and Patient Care Area Quality Assurance Inspections form a critical component of a hospital’s front line in the fight against infection. With the rise of COVID-19 (Coronavirus), programs like these help hospitals understand and employ best practices with regard to ensuring basic patient and caregiver safety.

Even before the onset of COVID-19, healthcare leadership has been pushing tirelessly for funding to support Infection Prevention and Control (IPC) programs to assure their facilities are taking the necessary steps to combat the spread of viruses and other infectious diseases. As an example one of our customers at Martinsburg VA Medical Center estimates in an internal cost benefit analysis the implementation of ExAM4Inspections would enable them to “reallocate 536 hours of IPC time currently spent performing administrative tasks to more specialized Infection Prevention and Control duties. Although the value of IPC time can be challenging to precisely quantify, reallocation towards additional prevention, training and education is worthwhile considering a single S. aureus bloodstream infection recently cost facilities more than $100,000.” This was of course written prior to the COVID-19 pandemic, but it hints at the scale of the cost reduction in human lives and dollars that could be achieved by leveraging the Salesforce AppExchange product ‘ExAM4Inspections’ to confirm proper standards are met, and to enable leadership to make necessary decisions and adjustments in real time.

MB&A has been awarded the CIO Applications Top 25 Salesforce Solution Providers of 2019. MB&A was recognized for their groundbreaking Salesforce AppExchange product ExAM (ExAM4Inspections.com) which is currently being used to enable adherence to standards at hospitals nationwide.

Learn More at ExAM4Inspections.com

Bradley Hilker
MB&A
+1 703-973-5404
email us here


Source: EIN Presswire

From Chill to Kill – Pheronym treated Nematodes Aggressively Disperse in Lower Temperatures

Pheromones’ role in EPN foraging to find host

Third Peer-Reviewed Study Shows Company’s Bio-remediation Technology Works in Cooler Weather, Expanding the Range for Deploying Nematode-based biocontrol

In essence, Pheronym’s Nemastim takes the Nematodes from chill, to kill.”

— Dr. Fatma Kaplan, CEO of Pheronym

DAVIS, CA, UNITED STATES, March 31, 2020 /EINPresswire.com/ — Pheronym, an ag-biotech pest control company, announced today the results of their third peer-reviewed study demonstrating the efficacy of their patented Nematism ™ pheromone extract for bio-remediation of agricultural pests. In a study to be published in Scientific Reports by Springer Nature, Dr. David Shapiro-
Ilan with the USDA-ARS, Dr. Ed Lewis, with the University of Idaho, and Dr. Fatma Kaplan, with Pheronym reported that nematodes treated with Pheronym’s pheromones still aggressively dispersed in temperatures as low as 15 degrees Celsius, which was superior to untreated nematodes. Most entomopathogenic (insect-killing) nematode species require 20 degrees or above for optimum activity.

The research, led by Dr. Kaplan with Pheronym, Inc., studied pheromones’ role in the stimulation of dispersal at temperatures from 15 to 30 degrees Celsius and how this is affected by nematodes’ foraging strategy.

“Nematodes typically reduce their dispersal or remain motionless in cooler temperatures. Expanding the temperature range downward for deploying beneficial nematodes means farmers can enhance the use of environmentally-friendly pest management solutions and thereby reduce harmful chemical inputs,” said Dr. Fatma Kaplan, CEO of Pheronym. “In essence, Pheronym’s Nemastim takes the Nematodes from chill, to kill.”

“Expanding the temperature range for the deployment of beneficial nematodes is a huge win for sustainable agriculture,” said Dr. David Shapiro, USDA-ARS. “It’s just one more reason for more aggressive commercial deployment of effective solutions like nematode pheromones.”

The new study can be found here www.nature.com/articles.
Pheronnym’s previous two peer-reviewed studies on efficacy and infectivity can be found here, Pheromone extracts act as boosters for entomopathogenic nematodes efficacy and here, Conspecific pheromone extracts enhance entomopathogenic infectivity.

About Pheronym:
Award-winning Pheronym is an ag-biotech pest management company that enables sustainable farming through its novel platform of nematode pheromones. Based in Merritt Island, Florida and Davis, California, the company uses a new pheromone to control plant-parasitic nematodes (microscopic roundworms) in an eco-friendly way and enhances beneficial nematodes’ efficacy to eliminate pest insects. Learn more at http://www.pheronym.com.

Karl Cameron Schiller
Pheronym, Inc.
+1 352-283-6967
email us here


Source: EIN Presswire

Untangling the Social Lives of Spiders

Scientists start to unravel the genetic basis of social behavior in spiders.

NEW YORK, UNITED STATES, March 31, 2020 /EINPresswire.com/ — The idea of a complex spider society—in which thousands of spiders live, hunt, and raise their young together in a single colony—is unsettling to many of us. We are perhaps lucky that this scene is relatively rare among arachnids. Among the 40,000 known species of spiders, the vast majority live solitary lives and often show aggression toward other spiders they encounter, even within their own species. There are fewer than 25 known species of social spiders, distributed broadly across 6 different families and 9 different genera. Not only do these spiders live in social groups, but they produce populations that grow over time as new offspring are added to the nest, enabling the capture of increasingly large prey as the colony expands, and even give rise to new daughter colonies. As social creatures ourselves, humans have long been interested in the evolutionary innovations that enable social cooperation. In a new article in Genome Biology and Evolution titled “Comparative genomics identifies putative signatures of sociality in spiders”, researchers provide a glimpse into the genetic underpinnings of how a solitary spider evolves into a social one.

The research, led by Dr. Chao Tong, a postdoc in the lab of Dr. Timothy Linksvayer at the University of Pennsylvania, represents one of the first comparative genomic studies to be conducted in spiders. According to Dr. Tong, “The high complexity and large size of spider genomes has constrained the development of genomic resources for spiders.” Because of this, earlier studies compared individual spider genomes to insect genomes and sought mainly to identify venom and silk genes. In the new study, however, a curiosity about the genetic basis of social life led Dr. Tong and his colleagues to compare the genomes of 7 spider species: two social species in the genus Stegodyphus that evolved sociality independently, and five solitary species from five different genera.

The analysis revealed a number of interesting findings. First, rapidly evolving genes in the two social species were involved not only in behavior but also in immunity, indicating that group living may require better defenses against pathogens that spread more easily in dense social groups. In contrast, genes that were rapidly evolving in the solitary species were enriched for energy metabolism processes. Dr. Tong notes that this is the opposite pattern from what is observed in social insects such as bees and ants, in which metabolic genes evolve more rapidly. Still, in both insects and spiders, there appear to be metabolic differences between solitary and social organisms that may reflect differences in hunting and feeding behaviors.

In addition, the researchers found that the genomes of the two social spiders exhibited a higher rate of evolution overall than those of the solitary species. While this might reflect a greater number of genes under positive selection, the authors are quick to point out that this pattern may also stem from demographic features that characterize social spiders, such as a female-skewed sex ratio (social spiders have more female offspring than males) and high levels of inbreeding. Perhaps most interesting of all, the new study identified a set of rapidly evolving genes that showed brain-specific expression and were enriched for social behavioral processes. These genes represent top candidates for those that influence social behavior and may have been involved in the evolution of spider sociality.

The researchers note an important limitation of their analysis: since the two social spiders they studied are from the same genus and they did not have access to a solitary spider from this genus, it is difficult to untangle which patterns are directly related to sociality and which may simply characterize spiders in the genus Stegodyphus—both social and non-social species. Thus, the group has already started their next project to verify the above patterns in more species, including more social spiders and their solitary relatives within the same genus. Realizing that the success of this endeavor may require establishing new collaborations due to the scarcity of spider genomic resources, Dr. Tong would like to put out a call to other researchers: “We welcome samples from other researchers, as we want to include as many spiders as possible in future studies, including social, subsocial, and solitary spider samples from multiple genera."

Casey McGrath
Society for Molecular Biology and Evolution
+1 617-850-2136
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

AnX Robotica Corp Receives 510(k) Clearance from FDA to Market its IntraMarX™ Radiopaque Markers

Radiopaque markers are used to measure colon transit time and they are the most basic and primary tool in evaluating disorders of colonic motility.

PLANO, TX, UNITED STATES, March 31, 2020 /EINPresswire.com/ — FOR IMMEDIATE RELEASE

AnX Robotica Corp receives 510(k) clearance from FDA to market its IntraMarX™ Radiopaque Markers
Plano, TX March 31st, 2020

AnX Robotica Corp (AnX) today announced that it has received FDA 510(k) clearance to market its IntraMarX™ Radiopaque Markers (ROM).

Radiopaque markers are used to measure colon transit time and they are the most basic and primary tool in evaluating disorders of colonic motility. The radiopaque marker test is the most widely used diagnostic testing method for colonic motility disorders. It is simple to perform as well as being cost effective.

“Our market research found that radiopaque markers have been increasingly difficult to obtain. Despite this, ROM’s remain the gold standard for diagnosis of GI motility disorders,” said Lee Linton, Director of Sales & Marketing at AnX Robotica Corp. AnX plans to make the markers available through its website with direct ordering and immediate delivery, direct to the physician, GI department or radiology department of the ordering facility. This is the first product of an entire platform of GI capsule related products which AnX plans to introduce beginning in 2020.

“After having so much difficulty getting radiopaque markers for evaluating colonic motility, it was terrific that AnX is now making this test available without delay for my patients. Many GI’s such as I have had to utilize more expensive and overburdensome tests due to the difficulty of accessing these markers. It is nice to now have an office-based method to evaluate constipation and slow transit disorders, and even to assess overflow diarrhea and correlate the results with patient symptoms”, said Dr. Douglas Drossman (Drossman Gastroenterology/Rome Foundation President Emeritus and COO).

AnX’s IntraMarX™ Radiopaque Markers are available in three (3) shapes, Round, Double-D and Tri-chamber for easy identification and location on x-rays. They are available in packages of 10 (10-pack) and (3 X 10-pack). The 3 X 10-pack includes one of each available shape.

The AnX website is, www.anxrobotics.com
Orders may also be placed by calling, 469-606-9495.

About AnX Corp
AnX Robotica has developed the NaviCam™ System, a robotic control platform for GI diagnostic and therapeutic applications. The NaviCam System utilizes advanced robotic technologies, innovative software & AI to give practitioners external control of capsules inside the body. AnX’s initial application is the NaviCam Stomach Capsule for visualization of the stomach. The NaviCam System is widely used with over 200,000 patients benefiting from the procedure in 2019 alone. AnX Robotica has also developed an advanced capsule for small bowl visualization (NaviCam™ SBXact) and a product for constipation (VibraBot™), with additional products forthcoming. AnX Robotica is based in Texas and California with worldwide sales.

Contact:
Lee Linton, Director of Sales & Marketing
(214) 707-1349
lee.linton@anxrobotics.com
www.anxrobotics.com

Lee Linton
AnX Robotica Corp
+1 214-707-1349
email us here


Source: EIN Presswire

The Political Animal: Are Thousands of Game Farms in the U.S. Spawning a Generation of Disease-Carrying Zombie Deer?

Wayne Pacelle

Wayne Pacelle

Animal Wellness Brands Logo

Deer Farms May Be a Next Threat to Wildlife and Human Health That We Aren’t Doing a Damn Thing About

WASHINGTON, DC, USA, March 30, 2020 /EINPresswire.com/ — By Wayne Pacelle

Private game farms keep deer behind big fences, slaughter them for meat or velvet, and invite fee-paying hunters to shoot some of the quarry in a guaranteed-kill arrangement. It’s about as sporting as shooting a deer in a pen in a zoo. But this startlingly large industry – with perhaps 4,000 enterprises in the United States, according to the North American Deer Farmers Association – has been driving the spread of Chronic Wasting Disease throughout the United States. It’s a brain-destroying disorder like Mad Cow Disease that turns the brains of deer, elk, and moose into Swiss cheese. It’s a threat to the captive deer and the wild ones. And maybe also to the people who consume the meat after the hunt is complete.

Wondering which animal industry is poised to spawn the next animal or human health epidemic like COVID-19? Well, here’s one candidate for the list of plagues in progress.

Perhaps the least noticed of the major animal exploitation industries in the United States, game farms quietly operate in more than half the states, with 60 percent of them in Michigan, Minnesota, Ohio, Pennsylvania, Wisconsin, and Texas. The deer are often bred with antlers so big and heavy that they can’t raise their heads. These commercial wildlife-killing enterprises have spread CWD to wild deer in more than two dozen states.

It’s thought that nose-to-nose interactions between captive and wild deer through fencing or deer escaping from farms are the most common forms of CWD transmission to free-roaming animals. But there is no live test for the disease and symptoms may not manifest for years, if ever. Trucking deer for sale between farms can allow the disease to spread overnight to areas previously without infections.

Not even hunters who are microbiologists can determine if the animals they slay in the wild and then serve up to their families have been infected with prions, the nearly indestructible agents of the disease. In fact, infected deer, less alert and fleet than their prion-free herd mates, may be more vulnerable to hunters, potentially increasing human exposure to CWD-tainted meat. Like Mad Cow Disease, CWD may infect people with its human variant Creutzfeld-Jakob Disease, causing dementia and a fatal brain disorder.

The abnormal proteins that cause CWD to survive in the soil for long periods of time also enable the disease to remain in the environment for years.

Minnesota is the latest state with a significant surge in CWD cases. The Minneapolis Star Tribune reports that after learning of a disease outbreak at a deer farm, the USDA pays farmers to “depopulate” their herds, slaughtering all of the animals. In the past three years the USDA has doled out over a half million dollars to deer farmers in Minnesota and Wisconsin, just as the federal agency has paid millions to cockfighters in California to kill their birds after two major avian influenza outbreaks there. Yes, you’ve read that right: the USDA has been compensating cockfighters and deer farmers for the disease-transmission problems they’ve been primarily responsible for incubating and spreading.

With state fish, wildlife and agriculture departments pointing to an abundance of deer eating crops, consuming ornamental shrubbery, spreading Lyme Disease, and being hit by cars by the tens of thousands on highways, one might ask why still more deer are being bred and then crowded in densities creating conditions ripe for the emergence of CWD.

CWD was first discovered at a deer farm in Colorado in the 1960s. Since then, it has spread to 25 states. Since the disease was detected in 2002 in Wisconsin – which has had thousands of confirmed cases — the state, as of a few years ago, had spent more than $45 million to contain its spread. But the state is apparently spending little now on the problem even as the outbreak gathers momentum. The order to shelter in place, apparently, has not been heeded by the deer, and the zombies are on the march.

Some conservation-minded sportsmen grasp the idea that the best way to stop the disease is to shutter the game farm. Even the Montana-based Boone and Crockett Club oppose the slaying of fenced, diseased animals with giant racks to preserve the sport itself from self-ruin. Yet still, too few voices within the hunting community are sounding the alarm about the threat.

Even prior to the detection of CWD in Montana’s wild deer population, Montana voters passed a ballot initiative banning captive hunts and halting the establishment of game farms. Other states have not been as foresighted and, despite CWD outbreaks, have not taken meaningful steps to phase out deer farms or to alert hunters to the impending health threats from eating infected animals. The two biggest hunting states, Pennsylvania and Texas, each have more than 1,000 deer farms, according to the industry trade group.

Deer farmers tout the revenues generated from the meat, hunts, and “velvet” from the antlers of the animals they breed, confine, and offer up for killing. But how can policy makers endorse this practice from an economic or wildlife management angle if the government must spend tens of millions of dollars to contain CWD, if CWD has the potential to devastate deer herds and cause a sharp decline in hunting license sales, and expose hunting families to the consumption of meat that might bring them dementia?

Here’s an area where true sportsmen and animal advocates have a shared purpose. By bringing a halt to deer farms, we have the potential to end the crass commercialization of wildlife and prevent the spread of a nearly indestructible prion that can kill animals and people. And with the nation having tens of millions of wild deer, what kind of lunacy is it to swell the deer population even more for these nefarious purposes?

Wayne Pacelle is the founder of Animal Wellness Action and two-time best-selling author of The Bond and Humane Economy

To make a donation to Animal Wellness Action please donate online here or mail to:

Animal Wellness Action
611 Pennsylvania Avenue SE #136
Washington, DC 20003

Wayne Pacelle
ANIMAL WELLNESS ACTION
+1 202-420-0446
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire